GENENTECH USA, INC: $37.5M Department of Health and Human Services Contract
Summary
The Department of Health and Human Services awarded a $37.5M delivery order to Genentech USA, Inc. for Xofluza tablets, a flu treatment. As Genentech is a private entity, no publicly traded companies are directly linked, but the contract signals continued government investment in antiviral stockpiling.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.Genentech is private; no direct public company exposure.
- 2.Contract supports pandemic preparedness but is modest in size.
- 3.No related legislation directly tied to this award.
Market Implications
This contract has negligible direct implications for US equity markets as the recipient is private. The broader healthcare sector may see indirect tailwinds from sustained government spending on medical countermeasures, but no specific tickers are impacted.
Full Analysis
The contract is a $37.5M delivery order from the Office of Assistant Secretary for Preparedness and Response (ASPR) to Genentech USA, Inc. for the procurement of Xofluza (baloxavir marboxil) 40mg and 80mg tablets, covering a period from September 2025 to September 2027. Xofluza is an antiviral medication for influenza, indicating this procurement is part of pandemic preparedness and medical countermeasure stockpiling. Genentech is a private biotechnology company and a wholly owned subsidiary of Roche Holding AG, which is publicly traded on the SIX Swiss Exchange but not on major US exchanges. Per analysis guidelines, no US-listed tickers are assigned. The contract is routine in size and scope, representing a standard replenishment or expansion of the Strategic National Stockpile. No related legislation directly authorizes this specific procurement, though broader healthcare preparedness bills like the WINGS Act (HR4805) and NIH Mentorship Modernization Act (S5295) support related public health infrastructure. Supply chain beneficiaries are not identifiable due to the private nature of the recipient. Historically, similar antiviral procurement contracts are recurring and do not create outsized market movements for private entities.
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
GLAXOSMITHKLINE, LLC: $45.5M Department of Health and Human Services Contract
GLAXOSMITHKLINE, LLC: $18.2M Department of Health and Human Services Contract
GLAXOSMITHKLINE, LLC: $27.3M Department of Health and Human Services Contract
FRESENIUS KABI, LLC: $24.4M Department of Health and Human Services Contract
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Enhancing Program Integrity and Integrity and Interagency Coordination in the Administration of the H-1B Nonimmigrant Visa Program
This executive order directs the Secretaries of State, Labor, and Homeland Security to coordinate with Commerce, Education, and the SBA when processing H-1B petitions, and requires them to consider whether the employer has engaged in layoffs of similarly situated U.S. workers within the past year. It also orders the Labor Department to review past labor condition applications for potential enforcement actions against sponsoring employers, effectively tightening scrutiny on H-1B usage, especially by outsourcing firms.
Accelerating Access To Veterans' Benefits And Employment Opportunities
This proclamation orders the Secretaries of War and Veterans Affairs to mandate rapid, ongoing digital sharing of military personnel and medical records, deploy AI-powered tools for benefits applications, and update existing IT contracts for interoperability. It also requires the Transition Assistance Program to connect separating service members to specific jobs or training programs before discharge.
Delivering Gold Standard Childhood Vaccine Recommendations for Americans
This executive order directs HHS to establish a 'Gold Standard' childhood vaccine schedule with fewer recommended vaccines than current CDC guidelines, mandates that MMR be administered as three separate single-disease shots when domestically available, and instructs the DOJ to challenge state vaccine mandates that do not provide religious or medical exemptions. It also orders HHS to develop alternative adjuvants to aluminum and improve vaccine safety monitoring, while preserving access to existing vaccines.
Contract Details
Recipient
GENENTECH USA, INC
Award Amount
$37,485,000
Awarding Agency
Department of Health and Human Services
Sub-Agency
Office of Assistant Secretary for Preparedness and Response
Contract Type
DELIVERY ORDER
Free — no credit card
Get the next market-moving signal before the news does
HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →